用于前列腺癌的三功能PSMA靶向构建体在LNCaP肿瘤中实现前所未有的定位
研究开发了一类三功能配体,同时具备高亲和力PSMA结合域、白蛋白结合基团和放射性金属螯合剂,在LNCaP细胞和小鼠模型中评估其PSMA亲和力、体内分布及肿瘤摄取,并与177Lu-PSMA-617比较。结果显示高亲和力配体肿瘤摄取显著高于177Lu-PSMA-617,最高达30.0 ± 6.9 %ID/g(177Lu-RPS-063,注射后4小时),但肾脏摄取普遍较高。作者认为这些配体可向肿瘤递送更大剂量(最高达4倍),其优异的肿瘤AUC值得进一步研究作为放射性配体治疗候选。
要点
- 三功能配体PSMA亲和力高(IC50=1-10 nM),与连接子长度成反比。
- 177Lu-RPS-063在注射后4小时肿瘤摄取达30.0 ± 6.9 %ID/g,显著高于177Lu-PSMA-617。
- 肾脏摄取普遍较高,仅最低亲和力的177Lu-RPS-067例外。
核心结论
- 三功能配体可实现比177Lu-PSMA-617更高的肿瘤摄取,预测向肿瘤递送的剂量最高可达4倍。
- 尽管观察到PSMA介导的肾脏摄取,但肿瘤曲线下面积(AUC)优异,值得进一步研究这些新型配体作为放射性配体治疗(RLT)的候选。
研究设计与样本
- 临床前研究:制备含三唑基苯基脲PSMA靶向基团、Nε-(2-(4-碘苯基)乙酰基)赖氨酸白蛋白结合基团和p-SCN-Bn-DOTA螯合剂的配体,连接子含0、3、4、6、8或12个重复单元。
- 在LNCaP细胞中测定PSMA亲和力;在荷LNCaP肿瘤异种移植小鼠中研究 uptake 和组织分布,并与177Lu-PSMA-617比较。
- 使用66Ga3+进行注射后24小时内的显像研究;使用177Lu3+在注射后4小时、24小时和96小时进行生物分布研究。
主要发现
- PSMA亲和力高(IC50 = 1-10 nM),且与连接子长度成反比。
- 肿瘤摄取与结合亲和力相关,在96小时内显著高于177Lu-PSMA-617。
- 最高摄取由177Lu-RPS-063实现(30.0 ± 6.9 %ID/g;注射后4小时)。
- 肾脏摄取普遍较高,但最低亲和力的配体177Lu-RPS-067例外。
- 每种化合物的血液清除均慢于177Lu-PSMA-617,清除速度与连接子长度成比例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Treatment of late-stage prostate cancer by targeted radiotherapeutics such as 131I-MIP-1095 and 177Lu-PSMA-617 has shown encouraging early results. Lu-177 is preferred to I-131 in clinical settings, but targeted radioligand therapy (RLT) with 177Lu-PSMA-617 has not reached its full potential due to insufficient dose delivery to the tumor. We recently developed a dual-targeting radioiodinated ligand, RPS-027, that targets PSMA and uses albumin binding to enable good tumor uptake and significantly reduced kidney uptake in a preclinical model. Further development of this ligand is limited by the inability to independently modify PSMA and albumin binding and the requirement of I-131 for therapeutic application. We therefore sought to devise a new class of trifunctional ligands for RLT with (1) a high-affinity PSMA-binding domain, (2) an albumin-binding group (ABG), and (3) a chelator for radiometals such as 68Ga3+, 177Lu3+ and 225Ac3+. METHODS: Ligands incorporating a triazolylphenylurea-containing PSMA-targeting group, an Nε-(2-(4-iodophenyl)acetyl)lysine ABG and the bifunctional chelator p-SCN-Bn-DOTA linked by a PEG-containing polymer containing 0,3,4,6,8 or 12 repeats were prepared. PSMA affinity was determined in LNCaP cells and uptake and tissue distribution was studied in mice bearing LNCaP tumor xenografts and compared to 177Lu-PSMA-617. Imaging studies were performed up to 24 h post-injection (p.i.) using 66Ga3+ and biodistribution studies at 4 h, 24 h and 96 h p.i. with 177Lu3+. RESULTS: PSMA affinity was high (IC50 = 1-10 nM) and inversely proportional to the linker length. Tumor uptake correlated with binding affinity and was significantly greater than for 177Lu-PSMA-617 over 96 h. The highest uptake was achieved with 177Lu-RPS-063 (30.0 ± 6.9 %ID/g; 4 h p.i.). Kidney uptake was generally high, with the exception of the lowest affinity ligand 177Lu-RPS-067. Each of the compounds showed slower blood clearance than 177Lu-PSMA-617, with clearance proportional to linker length. CONCLUSIONS: The high tumor uptake achieved with these trifunctional ligands predicts larger (up to 4×) doses delivered to the tumor than can be achieved with 177Lu-PSMA-617. Although PSMA-mediated kidney uptake was also observed, the exceptional area under the curve (AUC) in the tumor warrants further investigation of these novel ligands as candidates for RLT.
引用
- Kelly J, Amor-Coarasa A, Ponnala S, et al. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging. 2018. PMID: 29623376. doi:10.1007/s00259-018-4004-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。